Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 10/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386525 | 0.83 | GPR119 (0.56) | CCR5 | |
| SCHEMBL4118965 | 0.82 | JAK2 (0.46) | CCR5OPRD1ALDH1A1SMN1; SMN2TRPM8 | |
| SCHEMBL28613535 | 0.76 | CYP3A4 (0.54) | CCR5CYP3A4KCNH2 | |
| SCHEMBL28919139 | 0.75 | CYP3A4 (0.59) | CCR5CYP3A4 | |
| SCHEMBL12202570 | 0.73 | CCR5 (0.84) | CCR5CYP3A4KCNH2 | |
| SCHEMBL28598203 | 0.73 | CCR5 (0.49) | CCR5CYP3A4KCNH2OPRD1 | |
| SCHEMBL2896994 | 0.72 | L3MBTL3 (0.46) | CCR5KCNH2OPRD1 | |
| SCHEMBL4384809 | 0.72 | CCR5 (0.59) | CCR5KCNH2 | |
| SCHEMBL4074303 | 0.71 | HSD11B1 (0.53) | — | |
| SCHEMBL21047771 | 0.70 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551827-B1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | NOVARTIS AG | 2008-10-09 | — | — | US | disclosed |
| US-7399771-B2 | Piperidine derivatives as CCR5 inhibitors | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
| US-20060004047-A1 | Piperidine derivatives as ccr5 inhibitors | NOVARTIS AG (CH) | 2006-01-05 | — | — | US | disclosed |
| EP-1551827-A1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | Novartis AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031172-A1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | NOVARTIS AG (CH) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004047-A1 | Piperidine derivatives as ccr5 inhibitors | CCR5, CCR2, CCR1 | CCR5 1/4885CYP3A4 3290/4885KCNH2 2183/4885 |
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | CCR5, CCR2, CCR1 | CCR5 1/4885CYP3A4 3082/4885KCNH2 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.